首页|Development of a novel formulation method to prepare liposomal Epacadostat

Development of a novel formulation method to prepare liposomal Epacadostat

扫码查看
原文链接
  • NSTL
  • Elsevier
Background: One of the important metabolic pathways in cancer progression is tryptophan catabolism by the indoleamin-2,3-dioxygenase (IDO) enzyme, which suppresses the immune system and induces tolerance. Inhibition of IDO1 is an important therapeutic goal for immunotherapy in many cancers such as metastatic melanoma. Epacadostat (EPA) is a very strong inhibitor of IDO1, and its clinical studies are being performed in a higher clinical phase than other inhibitors. In this study, we have developed a new liposomal EPA formulation to reduce the dose, side effects, and treatment costs. Methods: Liposomes containing EPA were formulated using a novel remote loading method. Their morphology, particle size, surface charge, total phospholipid content, and drug loading were evaluated. Validation method studies to assay of EPA were carried out according to ICHQ2B guidelines. For in-vivo study, B16F10 melanoma bearing C57BL/6 mice were treated with the free or liposomal forms of EPA, and then monitored for tumor size and survival rate. Results: A validated method for EPA determination in liposomal form using UV-visible spectrophotometry was developed which was a precise, accurate and robust method. The particle size, zeta potential, and encapsulation efficacy of liposomes was 128.1 +/- 1.1 nm, -16.5 +/- 1 mV, and 64.9 +/- 3.5, respectively. The half maximal inhibitory concentration (IC50) of liposomal EPA was 64 ng/ml that was lower than free EPA (128 ng/ml). Invivo results also showed that tumor growth was slower in mice receiving liposomal EPA than in the group receiving free EPA. Conclusion: A new method was developed to load EPA into liposomes. Moreover, the use of the nanoliposomal EPA showed more efficacy than EPA in inhibiting the tumor growth in melanoma model. Therefore, it might be used in further clinical studies as a good candidate for immunotherapy alone or in combination with other treatments.

EpacadostatNanoliposomeMelanoma cancerIndoleamin-23-dioxygenase (IDO)

Tahaghoghi-Hajghorbani, Sahar、Khoshkhabar, Rahimeh、Rafiei, Alireza、Ajami, Abolghasem、Nikpoor, Amin Reza、Jaafari, Mahmoud Reza、Badiee, Ali

展开 >

Mashhad Univ Med Sci, Pharmaceut Technol Inst, Nanotechnol Res Ctr, Mashhad, Iran

Mazandaran Univ Med Sci, Sch Med, Dept Immunol, Mol & Cell Biol Res Ctr, Sari, Iran

Mazandaran Univ Med Sci, Sch Med, Dept Immunol, Sari, Iran

Hormozgan Univ Med Sci, Dept Immunol, Fac Med, Bandar Abbas, Iran

展开 >

2021

10.1016/j.ejps.2021.105954

European journal of pharmaceutical sciences

European journal of pharmaceutical sciences

ISTP
ISSN：0928-0987
年,卷(期)：2021.165
  • 2
  • 45